These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 3674850)

  • 1. In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori).
    Van Caekenberghe DL; Breyssens J
    Antimicrob Agents Chemother; 1987 Sep; 31(9):1429-30. PubMed ID: 3674850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro susceptibility of Campylobacter pyloridis to cimetidine, sucralfate, bismuth and sixteen antibiotics.
    Andreasen JJ; Andersen LP
    Acta Pathol Microbiol Immunol Scand B; 1987 Apr; 95(2):147-9. PubMed ID: 3591312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of clinical isolates of Campylobacter pylori to 24 antimicrobial and anti-ulcer agents.
    Glupczynski Y; Delmee M; Bruck C; Labbe M; Avesani V; Burette A
    Eur J Epidemiol; 1988 Jun; 4(2):154-7. PubMed ID: 3402574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergism between clindamycin and colloidal bismuth subcitrate against Helicobacter (Campylobacter) pylori in vitro.
    Vogt K; Hahn H
    Zentralbl Bakteriol; 1990 Nov; 274(2):246-9. PubMed ID: 2085373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The minimum inhibitory concentrations of various bismuth salts against Campylobacter pylori.
    Vogt K; Warrelmann M; Hahn H
    Zentralbl Bakteriol; 1989 Sep; 271(3):304-10. PubMed ID: 2803458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined activity of trospectomycin and colloidal bismuth subcitrate against Helicobacter pylori in vitro.
    Vogt K; Rodloff AC; Hahn H
    Infection; 1991; 19(3):138-9. PubMed ID: 1832417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solubility, absorption, and anti-Helicobacter pylori activity of bismuth subnitrate and colloidal bismuth subcitrate: In vitro data Do not predict In vivo efficacy.
    Phillips RH; Whitehead MW; Lacey S; Champion M; Thompson RP; Powell JJ
    Helicobacter; 2000 Sep; 5(3):176-82. PubMed ID: 10971684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative susceptibilities of Campylobacter pylori to norfloxacin and other agents.
    Shungu DL; Nalin DR; Gilman RH; Gadebusch HH; Cerami AT; Gill C; Weissberger B
    Antimicrob Agents Chemother; 1987 Jun; 31(6):949-50. PubMed ID: 3619429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activities of new oral beta-lactams and macrolides against Campylobacter pylori.
    García-Rodríguez JA; García Sánchez JE; García García MI; García Sánchez E; Muñoz Bellido JL
    Antimicrob Agents Chemother; 1989 Sep; 33(9):1650-1. PubMed ID: 2817868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents.
    McNulty CA; Dent J; Wise R
    Antimicrob Agents Chemother; 1985 Dec; 28(6):837-8. PubMed ID: 2935076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Susceptibility of Campylobacter pyloridis to antibiotics].
    Freland C; Massoubre B; Drugeon HB
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):809-12. PubMed ID: 3309819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility of Campylobacter pyloridis to 20 antimicrobial agents.
    Lambert T; Mégraud F; Gerbaud G; Courvalin P
    Antimicrob Agents Chemother; 1986 Sep; 30(3):510-1. PubMed ID: 3777915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of bismuth subcarbonate against Campylobacter pylori: do citrate ions improve antibacterial activity?
    Vogt K; Warrelmann M; Hahn H
    Zentralbl Bakteriol; 1990 May; 273(1):33-5. PubMed ID: 2363796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation of the action of metronidazole on Helicobacter pylori by omeprazole and bismuth subcitrate.
    Andersen LP; Colding H; Kristiansen JE
    Int J Antimicrob Agents; 2000 Apr; 14(3):231-4. PubMed ID: 10773493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
    Park KN; Hahm JS; Kim HJ
    Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S103-7. PubMed ID: 7735924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of Campylobacter pylori to colloidal bismuth subcitrate.
    Goodwin CS; Bell B; McCullough C; Turner M
    J Clin Pathol; 1989 Feb; 42(2):216-7. PubMed ID: 2921366
    [No Abstract]   [Full Text] [Related]  

  • 17. Susceptibility of clinical isolates of Campylobacter jejuni to twenty-five antimicrobial agents.
    Lariviere LA; Gaudreau CL; Turgeon FF
    J Antimicrob Chemother; 1986 Dec; 18(6):681-5. PubMed ID: 3493235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis.
    Goodwin CS; Blake P; Blincow E
    J Antimicrob Chemother; 1986 Mar; 17(3):309-14. PubMed ID: 3700291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo susceptibility of Campylobacter pylori.
    Graham DY; Klein PD; Opekun AR; Smith KE; Polasani RR; Evans DJ; Evans DG; Alpert LC; Michaletz PA; Yoshimura HH
    Am J Gastroenterol; 1989 Mar; 84(3):233-8. PubMed ID: 2919580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy: a prospective randomized controlled trial.
    Kung NN; Sung JJ; Yuen NW; Li TH; Ng PW; Lai WM; Lui YH; Lam KN; Choi CH; Leung EM
    Am J Gastroenterol; 1999 Mar; 94(3):721-4. PubMed ID: 10086657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.